MoonLake Reports Q1 Financials: Cash Balance at $357.9M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy MLTX?
MoonLake reported its financial results for the first quarter of 2026. As of March 31, 2026, MoonLake held cash, cash equivalents and short-term marketable debt securities of $357.9M. The company expects to have sufficient capital to fund its operating expenses and capital expenditure requirements to the end of 2027. MoonLake's debt facility with Hercules Capital provides up to $400M in additional non-dilutive funds to support future funding needs. Research and development expenses were $54.5M for the three months ended March 31, 2026, which was similar to the $56.0M for the three months ended December 31, 2025. General and administrative expenses were $15.5M for the three months ended March 31, 2026, compared to $9.2M for the three months ended December 31, 2025. The increase of $6.3M was primarily related to $4.8M in accelerated expense recognition due to a voluntary cancellation of unvested stock option awards for no consideration.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MLTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MLTX
Wall Street analysts forecast MLTX stock price to rise
12 Analyst Rating
9 Buy
2 Hold
1 Sell
Moderate Buy
Current: 18.840
Low
5.00
Averages
24.10
High
45.00
Current: 18.840
Low
5.00
Averages
24.10
High
45.00
About MLTX
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trump Rejects Iran's Revised Proposal Amid Geopolitical Tensions
- Trump's Proposal Rejection: Trump labeled Iran's latest sanctions relief and uranium export proposal as 'totally unacceptable' on social media, potentially escalating tensions in the Middle East and impacting global market sentiment.
- Market Reaction: U.S. stock futures edged lower on Monday morning, with S&P 500 and Dow futures declining by 0.1% while Nasdaq futures remained flat, indicating investor caution ahead of upcoming economic data amid geopolitical developments.
- Chip Sector Momentum: Memory chip stocks like Micron (MU) and Everspin (MRAM) continued to dominate retail chatter, with Everspin's stock surging 35% in early trading, reflecting strong momentum in the AI infrastructure trade.
- Biotech Stocks in Focus: Biotech stocks such as Moderna (MRNA) and Novavax (NVAX) garnered attention, while MoonLake Immunotherapeutics (MLTX) trended high after a positive FDA meeting, showcasing investor confidence in new drug developments.
See More
U.S. Stock Futures Decline as Oil Prices Exceed $100 Again
- Market Sentiment Decline: U.S. stock futures fell overnight on Sunday, with Dow futures down 0.41%, S&P 500 futures down 0.25%, and Nasdaq 100 futures down 0.16%, as Trump's rejection of Iran's peace proposal heightened concerns over prolonged global energy supply tightness.
- Oil Price Surge: Brent crude futures exceeded $100 per barrel again, trading at approximately $104.85, while WTI crude futures rose by 3.89% to $99.13, indicating market expectations of future supply shortages amid ongoing geopolitical tensions.
- Inflation Data Watch: Investors are keenly awaiting U.S. inflation data set to be released on Tuesday, which will provide critical insights into potential interest rate movements, influencing market strategies and investment decisions.
- Tech Stocks Rally: Micron Technology's stock surged over 7% in overnight trading, driven by strong demand for memory chips, with a staggering 709% increase over the past year, highlighting a robust recovery in the semiconductor sector.
See More
MoonLake Receives FDA Approval for Drug Label Update
- FDA Label Approval: MoonLake announced that the FDA agreed to include results from the Phase 2 Mira study and Phase 3 Vela trials in the drug label for Sonelokimab, enhancing the drug's approval prospects for treating chronic skin conditions and potentially boosting market recognition and sales potential.
- Price Target Upgrade: Clear Street maintained a ‘Buy’ rating on MLTX with a price target of $70, implying a 310% upside from current levels, reflecting strong market confidence and growth expectations for Sonelokimab.
- Strong Cash Position: As of March 31, MoonLake held $357.9 million in cash, expected to fund operations through the end of 2027, while also having access to up to $400 million in non-dilutive funding through Hercules Capital, ensuring continued investment in R&D and market expansion.
- Impressive Clinical Data: In the Vela trials, 62% of patients achieved significant improvement after 40 weeks, with 43% of patients in the Mira study experiencing substantial symptom relief, showcasing Sonelokimab's strong efficacy and positioning it as a potential “best-in-class” treatment in the market.
See More
MoonLake Achieves Positive Consensus with FDA on BLA Submission for Sonelokimab
- FDA Meeting Outcome: On April 1, 2026, MoonLake reached a consensus with the FDA during its final pre-BLA meeting, confirming the acceptability of MIRA trial data to establish sonelokimab's effectiveness in HS, with BLA submission planned for the end of September 2026, marking a significant advancement in treatment options.
- Label Strategy Defined: The FDA agreed to include VELA-TEEN trial data in the label, covering patients aged 12 and above, with the label expected to feature a ~43% HiSCR75 response rate from the MIRA trial, showcasing the drug's outstanding performance in clinical trials and enhancing market competitiveness.
- Strong Financial Position: As of March 31, 2026, MoonLake reported $357.9 million in cash and short-term marketable debt securities, indicating sufficient capital to fund operations through the end of 2027, reflecting the company's financial stability for R&D and market initiatives.
- Upcoming Milestones: The company anticipates releasing 52-week data from the VELA-1 and VELA-2 trials within the next 12 months and primary endpoint results from the IZAR-1 trial in mid-2026, further advancing the clinical development of sonelokimab.
See More
CEO Jorge Santos da Silva Sells 150,000 Shares of MoonLake Immunotherapeutics
- Transaction Scale Analysis: CEO Jorge Santos da Silva sold 150,000 shares of MoonLake Immunotherapeutics on April 10 and 13, 2026, through multiple open-market transactions valued at approximately $2.8 million, indicating a sale size above his average of 107,000 shares and marking his second-largest single sale since October 2023.
- Impact on Ownership Proportion: This transaction reduced Santos da Silva's direct ownership by 4.9%, leaving him with 2,924,893 shares, which indicates he still retains a significant stake, reflecting confidence in the company's future prospects.
- Market Reaction and Outlook: Despite MoonLake's stock price plummeting from a 52-week high of $62.75 due to disappointing clinical trial results for Sonelokimab, the recent FDA fast track designation may expedite market entry, providing a glimmer of hope for investors.
- Financial Overview: As of the end of 2025, MoonLake had $394 million in cash, with quarterly operating expenses around $65 million, suggesting the company has sufficient funds to sustain operations for a while, but investors must possess a high risk tolerance to navigate future uncertainties.
See More
CEO Jorge Santos da Silva Sells 150,000 Shares of MoonLake Immunotherapeutics
- Executive Sell-off: CEO Jorge Santos da Silva sold 150,000 shares of MoonLake Immunotherapeutics on April 10 and 13, 2026, for approximately $2.75 million, representing 4.9% of his holdings, which reduces his direct ownership to 2,924,893 shares, potentially signaling concerns about the company's future prospects.
- Market Performance Decline: MoonLake's stock has significantly dropped from a 52-week high of $62.75 reached last September, primarily due to disappointing clinical trial results for its Sonelokimab therapy; although the company recently received FDA fast track designation, its recovery hinges on the outcomes of ongoing trials.
- Financial Condition Analysis: As of the end of 2025, MoonLake had $394 million in cash with quarterly operating expenses around $65 million, providing sufficient runway for operations, but the lack of revenue until FDA approval poses a risk, necessitating investors to have a high-risk tolerance.
- Investment Caution: Despite MoonLake's potential in the biotech sector, analysts have noted that it was not included in the current list of top investment stocks, urging caution for investors considering entry, especially amid market volatility and uncertain clinical outcomes.
See More
Trump Rejects Iran's Revised Proposal Amid Geopolitical Tensions
- Trump's Proposal Rejection: Trump labeled Iran's latest sanctions relief and uranium export proposal as 'totally unacceptable' on social media, potentially escalating tensions in the Middle East and impacting global market sentiment.
- Market Reaction: U.S. stock futures edged lower on Monday morning, with S&P 500 and Dow futures declining by 0.1% while Nasdaq futures remained flat, indicating investor caution ahead of upcoming economic data amid geopolitical developments.
- Chip Sector Momentum: Memory chip stocks like Micron (MU) and Everspin (MRAM) continued to dominate retail chatter, with Everspin's stock surging 35% in early trading, reflecting strong momentum in the AI infrastructure trade.
- Biotech Stocks in Focus: Biotech stocks such as Moderna (MRNA) and Novavax (NVAX) garnered attention, while MoonLake Immunotherapeutics (MLTX) trended high after a positive FDA meeting, showcasing investor confidence in new drug developments.
See More
U.S. Stock Futures Decline as Oil Prices Exceed $100 Again
- Market Sentiment Decline: U.S. stock futures fell overnight on Sunday, with Dow futures down 0.41%, S&P 500 futures down 0.25%, and Nasdaq 100 futures down 0.16%, as Trump's rejection of Iran's peace proposal heightened concerns over prolonged global energy supply tightness.
- Oil Price Surge: Brent crude futures exceeded $100 per barrel again, trading at approximately $104.85, while WTI crude futures rose by 3.89% to $99.13, indicating market expectations of future supply shortages amid ongoing geopolitical tensions.
- Inflation Data Watch: Investors are keenly awaiting U.S. inflation data set to be released on Tuesday, which will provide critical insights into potential interest rate movements, influencing market strategies and investment decisions.
- Tech Stocks Rally: Micron Technology's stock surged over 7% in overnight trading, driven by strong demand for memory chips, with a staggering 709% increase over the past year, highlighting a robust recovery in the semiconductor sector.
See More
MoonLake Receives FDA Approval for Drug Label Update
- FDA Label Approval: MoonLake announced that the FDA agreed to include results from the Phase 2 Mira study and Phase 3 Vela trials in the drug label for Sonelokimab, enhancing the drug's approval prospects for treating chronic skin conditions and potentially boosting market recognition and sales potential.
- Price Target Upgrade: Clear Street maintained a ‘Buy’ rating on MLTX with a price target of $70, implying a 310% upside from current levels, reflecting strong market confidence and growth expectations for Sonelokimab.
- Strong Cash Position: As of March 31, MoonLake held $357.9 million in cash, expected to fund operations through the end of 2027, while also having access to up to $400 million in non-dilutive funding through Hercules Capital, ensuring continued investment in R&D and market expansion.
- Impressive Clinical Data: In the Vela trials, 62% of patients achieved significant improvement after 40 weeks, with 43% of patients in the Mira study experiencing substantial symptom relief, showcasing Sonelokimab's strong efficacy and positioning it as a potential “best-in-class” treatment in the market.
See More
MoonLake Achieves Positive Consensus with FDA on BLA Submission for Sonelokimab
- FDA Meeting Outcome: On April 1, 2026, MoonLake reached a consensus with the FDA during its final pre-BLA meeting, confirming the acceptability of MIRA trial data to establish sonelokimab's effectiveness in HS, with BLA submission planned for the end of September 2026, marking a significant advancement in treatment options.
- Label Strategy Defined: The FDA agreed to include VELA-TEEN trial data in the label, covering patients aged 12 and above, with the label expected to feature a ~43% HiSCR75 response rate from the MIRA trial, showcasing the drug's outstanding performance in clinical trials and enhancing market competitiveness.
- Strong Financial Position: As of March 31, 2026, MoonLake reported $357.9 million in cash and short-term marketable debt securities, indicating sufficient capital to fund operations through the end of 2027, reflecting the company's financial stability for R&D and market initiatives.
- Upcoming Milestones: The company anticipates releasing 52-week data from the VELA-1 and VELA-2 trials within the next 12 months and primary endpoint results from the IZAR-1 trial in mid-2026, further advancing the clinical development of sonelokimab.
See More
CEO Jorge Santos da Silva Sells 150,000 Shares of MoonLake Immunotherapeutics
- Transaction Scale Analysis: CEO Jorge Santos da Silva sold 150,000 shares of MoonLake Immunotherapeutics on April 10 and 13, 2026, through multiple open-market transactions valued at approximately $2.8 million, indicating a sale size above his average of 107,000 shares and marking his second-largest single sale since October 2023.
- Impact on Ownership Proportion: This transaction reduced Santos da Silva's direct ownership by 4.9%, leaving him with 2,924,893 shares, which indicates he still retains a significant stake, reflecting confidence in the company's future prospects.
- Market Reaction and Outlook: Despite MoonLake's stock price plummeting from a 52-week high of $62.75 due to disappointing clinical trial results for Sonelokimab, the recent FDA fast track designation may expedite market entry, providing a glimmer of hope for investors.
- Financial Overview: As of the end of 2025, MoonLake had $394 million in cash, with quarterly operating expenses around $65 million, suggesting the company has sufficient funds to sustain operations for a while, but investors must possess a high risk tolerance to navigate future uncertainties.
See More
CEO Jorge Santos da Silva Sells 150,000 Shares of MoonLake Immunotherapeutics
- Executive Sell-off: CEO Jorge Santos da Silva sold 150,000 shares of MoonLake Immunotherapeutics on April 10 and 13, 2026, for approximately $2.75 million, representing 4.9% of his holdings, which reduces his direct ownership to 2,924,893 shares, potentially signaling concerns about the company's future prospects.
- Market Performance Decline: MoonLake's stock has significantly dropped from a 52-week high of $62.75 reached last September, primarily due to disappointing clinical trial results for its Sonelokimab therapy; although the company recently received FDA fast track designation, its recovery hinges on the outcomes of ongoing trials.
- Financial Condition Analysis: As of the end of 2025, MoonLake had $394 million in cash with quarterly operating expenses around $65 million, providing sufficient runway for operations, but the lack of revenue until FDA approval poses a risk, necessitating investors to have a high-risk tolerance.
- Investment Caution: Despite MoonLake's potential in the biotech sector, analysts have noted that it was not included in the current list of top investment stocks, urging caution for investors considering entry, especially amid market volatility and uncertain clinical outcomes.
See More
